Summary of hERG1 and VEGF receptor expression in AML cell lines of different FAB phenotypes
| Cell line . | FAB . | hERG1 . | FLT-1 . | KDR . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PCR . | WB . | |||||||||
| 1A . | 1B . | PCR . | WB . | p-Tyr level . | PCR . | WB . | p-Tyr . | |||
| FLG 29.1 | M5 | + | + | +++ | + | + | 3.6 | − | − | n.d. |
| K562 | acute phase of CML | + | + | +++ | + | ++ | 2.2 | − | − | n.d. |
| NB4 | M3 | + | ++ | +++ | + | + | 2.9 | − | − | n.d. |
| KG1 | M1 | + | ++ | ++ | + | + | 2.4 | − | − | n.d. |
| TF1 | M6 | + | + | ++ | + | + | 1.9 | − | − | n.d. |
| Cell line . | FAB . | hERG1 . | FLT-1 . | KDR . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PCR . | WB . | |||||||||
| 1A . | 1B . | PCR . | WB . | p-Tyr level . | PCR . | WB . | p-Tyr . | |||
| FLG 29.1 | M5 | + | + | +++ | + | + | 3.6 | − | − | n.d. |
| K562 | acute phase of CML | + | + | +++ | + | ++ | 2.2 | − | − | n.d. |
| NB4 | M3 | + | ++ | +++ | + | + | 2.9 | − | − | n.d. |
| KG1 | M1 | + | ++ | ++ | + | + | 2.4 | − | − | n.d. |
| TF1 | M6 | + | + | ++ | + | + | 1.9 | − | − | n.d. |
PCR results are expressed as −, not expressed; +, expressed. WB results are expressed as −, not expressed; +, low level of expression; ++, medium level of expression; +++, high level of expression; n.d., not determined. A densitometric analysis of FLT-1 tyrosine phosphorylation in AML cell lines stimulated with BSA or VEGF was performed as described in ′Patients, materials, and methods′; data are reported in the ′FLT-1: p-Tyr level′ lane and are expressed as n-fold increase in VEGF-treated cells compared with BSA-treated cells.